Geode Capital Management
ACRV icon

Geode Capital Management’s Acrivon Therapeutics ACRV Stock Holding History

Geode Capital Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$329K Buy
236,391
+38,168
+19% +$66.6K ﹤0.01% 3733
2025
Q4 		$478K Buy
198,223
+6,190
+3% +$13.5K ﹤0.01% 3599
2025
Q3 		$348K Buy
192,033
+27,671
+17% +$38.9K ﹤0.01% 3738
2025
Q2 		$196K Sell
164,362
-141,749
-46% -$195K ﹤0.01% 3883
2025
Q1 		$622K Buy
306,111
+4,722
+2% +$25.4K ﹤0.01% 3469
2024
Q4 		$1.81M Sell
301,389
-714
-0.2% -$5.19K ﹤0.01% 3165
2024
Q3 		$2.12M Sell
302,103
-6,290
-2% -$49.6K ﹤0.01% 3112
2024
Q2 		$1.79M Buy
308,393
+65,547
+27% +$528K ﹤0.01% 3152
2024
Q1 		$1.74M Buy
242,846
+53,646
+28% +$249K ﹤0.01% 3171
2023
Q4 		$931K Sell
189,200
-359
-0.2% -$1.9K ﹤0.01% 3382
2023
Q3 		$1.81M Buy
189,559
+11,106
+6% +$128K ﹤0.01% 3102
2023
Q2 		$2.31M Buy
178,453
+3,049
+2% +$36.9K ﹤0.01% 3063
2023
Q1 		$2.23M Buy
+175,404
New +$2.95M ﹤0.01% 2979

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management's ACRV Position: Q1 2026 in Review

Geode Capital Management increased its Acrivon Therapeutics (ACRV) stake by 19% in Q1 2026, buying an estimated $66.6K and bringing the position to 236,391 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #3733.

Geode Capital Management first reported a position in ACRV in Q1 2023 and has held it in 13 quarters since. The position peaked at $2.31M in Q2 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Geode Capital Management held 236,391 shares of Acrivon Therapeutics worth $329K as of Q1 2026.
  • Geode Capital Management bought 38,168 Acrivon Therapeutics shares in Q1 2026, an estimated $66.6K.
  • Acrivon Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3733 holding.
  • Geode Capital Management first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Geode Capital Management's Acrivon Therapeutics position peaked at $2.31M in Q2 2023.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.